Sarah Cannon Research Institute

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

Oncology

Dr Meredith McKean interview with Nicole Raleigh

ESMO 2024 – Dr Meredith McKean

In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.

News

Boehringer and Sarah Cannon team for immune-oncology venture

Partnership will seek to develop two immune checkpoint inhibitor candidates.

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

ESMO 2024 – Dr Meredith McKean

Boehringer and Sarah Cannon team for immune-oncology venture

Roche, Viking, and Syntis showcase obesity drug candidates

Discover a new era of healthcare panel engagement: Grounded ...

Sarah Cannon Research Institute

Editor's Picks